Nat Commun:北大罗金才课题组等揭示血管内皮细胞分泌新机制

2017-03-08 佚名 生物帮

2017 年 3 月 3 日,国际学术权威刊物自然出版集团旗下子刊《Nature Communications》杂志在线发表了北京大学分子医学研究所罗金才教授研究组和中国科学院生物物理研究所李栋研究组合作的一篇研究论文,研究最新发现细胞黏附斑分子 Zyxin 是一个全新的 WP 小体分泌调控分子。论文题目为“Zyxin regulates endothelial von Willebrand fa

2017 年 3 月 3 日,国际学术权威刊物自然出版集团旗下子刊《Nature Communications》杂志在线发表了北京大学分子医学研究所罗金才教授研究组和中国科学院生物物理研究所李栋研究组合作的一篇研究论文,研究最新发现细胞黏附斑分子 Zyxin 是一个全新的 WP 小体分泌调控分子。论文题目为“Zyxin regulates endothelial von Willebrand factor secretion by reorganizing actin filaments around exocytic granules”。博士研究生韩晓帆和李品为该项工作的第一作者。罗金才教授以及李栋研究员为论文共同通讯作者。

内皮细胞构成血管的最内层,介于管壁与血液之间。基于这种独特的位置,内皮细胞在响应外界刺激、维持循环系统稳定中起着重要作用,其中分泌是内皮细胞应对刺激的一种重要手段。Weibel palade 小体 (WP 小体) 是血管内皮细胞特有的分泌囊泡,储存有多种凝血和炎症相关因子,如 von Willebrand 因子 (VWF) 等。鉴于内皮细胞 WP 小体的分泌是一种血管损伤防御反应的关键机制,揭示其分子调控机制对防治出血、炎症等关联疾病具有重要意义。

罗金才课题组发现下调人原代血管内皮细胞的 Zyxin 基因表达能显着抑制 cAMP 激动剂引起的 VWF 分泌;Zyxin 敲除后小鼠呈现出血时间延长、血栓形成减慢等表型。这些结果说明,Zyxin 介导的内皮细胞分泌功能,对血管损伤修复和血栓形成起到不可或缺的作用。为了弄清作为斑联蛋白的 Zyxin 何以能够调控细胞分泌,罗金才课题组采用最新发展的活细胞超高分辨率成像系统,首次发现 Zyxin 及其结合蛋白α-actinin 对细胞膜下囊泡周围的微丝分子网络进行重构,通过形成环状“手脚架”结构对囊泡的分泌进行精确的时间、空间调控。该项研究不仅发现了一个调节内皮细胞分泌的新型分子 Zyxin,提供了治疗出血及血栓性疾病的潜在靶标,而且首次在活细胞中观察到膜下微丝分子网络与囊泡的相互作用,提出一个具有广泛意义的骨架调节囊泡分泌新模型,为以后研究囊泡和骨架的作用及机制提供了新思路。
原始出处:
Xiaofan Han,Pin Li,Zhenghao Yang,Xiaoshuai Huang,et al.Zyxin regulates endothelial von Willebrand factor secretion by reorganizing actin filaments around exocytic granules.Nature Communications 8, Article number: 14639(2017)doi:10.1038/ncomms14639

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086950, encodeId=693e2086950d2, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Nov 03 10:24:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936596, encodeId=66d61936596bc, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Fri Jul 07 16:24:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807310, encodeId=514d180e31073, content=<a href='/topic/show?id=f779e963363' target=_blank style='color:#2F92EE;'>#罗金才#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79633, encryptionId=f779e963363, topicName=罗金才)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Aug 27 05:24:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682286, encodeId=09a416822867b, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Oct 17 01:24:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881720, encodeId=144d1881e20d2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 14 13:24:00 CST 2017, time=2017-04-14, status=1, ipAttribution=)]
    2017-11-03 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086950, encodeId=693e2086950d2, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Nov 03 10:24:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936596, encodeId=66d61936596bc, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Fri Jul 07 16:24:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807310, encodeId=514d180e31073, content=<a href='/topic/show?id=f779e963363' target=_blank style='color:#2F92EE;'>#罗金才#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79633, encryptionId=f779e963363, topicName=罗金才)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Aug 27 05:24:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682286, encodeId=09a416822867b, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Oct 17 01:24:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881720, encodeId=144d1881e20d2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 14 13:24:00 CST 2017, time=2017-04-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086950, encodeId=693e2086950d2, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Nov 03 10:24:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936596, encodeId=66d61936596bc, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Fri Jul 07 16:24:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807310, encodeId=514d180e31073, content=<a href='/topic/show?id=f779e963363' target=_blank style='color:#2F92EE;'>#罗金才#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79633, encryptionId=f779e963363, topicName=罗金才)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Aug 27 05:24:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682286, encodeId=09a416822867b, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Oct 17 01:24:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881720, encodeId=144d1881e20d2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 14 13:24:00 CST 2017, time=2017-04-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086950, encodeId=693e2086950d2, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Nov 03 10:24:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936596, encodeId=66d61936596bc, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Fri Jul 07 16:24:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807310, encodeId=514d180e31073, content=<a href='/topic/show?id=f779e963363' target=_blank style='color:#2F92EE;'>#罗金才#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79633, encryptionId=f779e963363, topicName=罗金才)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Aug 27 05:24:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682286, encodeId=09a416822867b, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Oct 17 01:24:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881720, encodeId=144d1881e20d2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 14 13:24:00 CST 2017, time=2017-04-14, status=1, ipAttribution=)]
    2017-10-17 gwc392
  5. [GetPortalCommentsPageByObjectIdResponse(id=2086950, encodeId=693e2086950d2, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Nov 03 10:24:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936596, encodeId=66d61936596bc, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Fri Jul 07 16:24:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807310, encodeId=514d180e31073, content=<a href='/topic/show?id=f779e963363' target=_blank style='color:#2F92EE;'>#罗金才#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79633, encryptionId=f779e963363, topicName=罗金才)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Aug 27 05:24:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682286, encodeId=09a416822867b, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Tue Oct 17 01:24:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881720, encodeId=144d1881e20d2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 14 13:24:00 CST 2017, time=2017-04-14, status=1, ipAttribution=)]
    2017-04-14 liye789132251

相关资讯

脓毒症时血管内皮细胞与血管平滑肌细胞相互作用的研究进展

本文经《中华医学杂志》社有限责任公司授权,仅限于非商业应用。 作者:张艺森 徐晓涵 孙炳伟 江苏大学附属医院烧伤整形科 脓毒症是严重创伤、休克及感染等临床急危重症患者的常见严重并发症之一,进一步发展可导致脓毒性休克、多器官功能障碍综合征(MODS)。一份来自北美的流行病学调查结果显示,美国每年有75万例脓毒症患者,其中9%发展为严重脓毒症,3

脓毒症时血管内皮细胞与血管平滑肌细胞相互作用的研究进展

脓毒症是严重创伤、休克及感染等临床急危重症患者的常见严重并发症之一,进一步发展可导致脓毒性休克、多器官功能障碍综合征(MODS)。一份来自北美的流行病学调查结果显示,美国每年有75万例脓毒症患者,其中9%发展为严重脓毒症,3%发展为脓毒性休克,超过21万人(28%)死亡。虽然对脓毒症病理生理机制进行的研究涉及了细胞和分子机制,但病死率仍居高不下,最主要的因素是顽固性血管低反应和多器官功能衰竭(

Circ Res: PPIs可加速血管内皮细胞的老化

Circ Res: PPIs可加速血管内皮细胞的老化近日来自休斯敦卫理公会研究院的一项新的研究揭示了质子泵抑制剂诱导身体健康问题的机制,该研究已发表于Circulation Research。质子泵抑制剂(PPI)是治疗胃食管反流的常用药物,目前供患者长期使用而并没有医疗监督。最近的研究结果表明,PPI的使用与心血管、肾脏和神经系统疾病的发生有关。该研究探究了PPIs对患者血管内皮功能障碍和老化的

Cancer Cell:重编程的血管促进肿瘤扩散

血管在肿瘤的生长和扩散中起关键作用。衬于血管内壁的细胞(内皮细胞)和肿瘤细胞接触紧密,互相影响。领导亥姆霍兹德国癌症研究中心(DKFZ)、海德堡大学曼海姆临床医学院初级研究组的Andreas Fischer研究员及其同事正在从事该相互作用的研究。他们的团队发现,信号分子Notch的活化型在肿瘤血管里高表达。在来自肺、乳腺、肠部肿瘤的血管内衬细胞里,该活化受体的表达水平显着高于正常器官。研究者同时发

Circulation:科学家首次将人成纤维细胞成功转化为血管内皮细胞

近日,一项发表于国际杂志Circulation上的研究论文中,来自休斯顿卫理公会研究所的研究人员成功地将人类机体的疤痕细胞转化成为血管细胞,该研究发现或为开发修复损伤组织的疗法以及改善机体组织供血、氧气、营养的新方法提供了一定的帮助和希望。John Cooke教授表示,据我们所知,本文研究是首次利用小分子和蛋白来完成治疗细胞类型的分化转移,在特殊情况下我们就可以将成纤维细胞转化成为所需的细胞类型。

SCRT:胎盘间充质干细胞治疗缺血性疾病又有新发现

近日,国家干细胞工程技术研究中心主任韩忠朝团队发表在Stem Cell Research & Therapy上的一篇题为《VCAM-1+胎盘绒毛膜间充质干细胞显示出强有力促血管生成活性》的文章受到国内外相关领域的高度关注。该文章阐述了血管细胞黏附分子-1+(VCAM-1+)胎盘绒毛膜间充质干细胞(CV-MSC)具有良好的促血管生成活性,成为理论走向临床治疗的重要一步。 许多研究已经证